Recombinant Human ANGPTL3, N-His

Description of Recombinant Human ANGPTL3, N-His

Introduction

Recombinant Human ANGPTL3 is a protein that is produced through genetic engineering techniques, also known as recombinant protein. It is a member of the angiopoietin-like protein family and plays a crucial role in lipid metabolism and cardiovascular health. In this article, we will explore the structure, activity, and potential applications of Recombinant Human ANGPTL3.

Structure of Recombinant Human ANGPTL3

Recombinant Human ANGPTL3 is a 460 amino acid protein with a molecular weight of approximately 55 kDa. It consists of an N-terminal coiled-coil domain, a central fibrinogen-like domain, and a C-terminal domain. The coiled-coil domain is responsible for protein homodimerization, while the fibrinogen-like domain is critical for binding to lipoprotein lipase (LPL) and endothelial lipase (EL). The C-terminal domain is involved in the inhibition of LPL and EL activity.

Activity of Recombinant Human ANGPTL3

Recombinant Human ANGPTL3 is a potent inhibitor of LPL and EL, two key enzymes involved in lipid metabolism. LPL is responsible for breaking down triglycerides in the blood, while EL plays a crucial role in the clearance of high-density lipoprotein (HDL) cholesterol. By inhibiting these enzymes, ANGPTL3 increases the levels of triglycerides and HDL cholesterol in the blood, leading to a decrease in low-density lipoprotein (LDL) cholesterol, also known as “bad” cholesterol.

Moreover, ANGPTL3 has been shown to inhibit the uptake of fatty acids by cells, resulting in a decrease in lipid accumulation in tissues. This activity makes ANGPTL3 a potential therapeutic target for the treatment of obesity and related metabolic disorders.

Applications of Recombinant Human ANGPTL3

Due to its role in lipid metabolism and cardiovascular health, Recombinant Human ANGPTL3 has been studied extensively for its potential applications. One of the most promising applications is in the treatment of dyslipidemia, a condition characterized by abnormal levels of lipids in the blood. ANGPTL3 inhibitors have shown promising results in clinical trials for the treatment of dyslipidemia, with significant reductions in LDL cholesterol and triglyceride levels.

Another potential application of Recombinant Human ANGPTL3 is in the treatment of obesity and related metabolic disorders. By inhibiting the uptake of fatty acids by cells, ANGPTL3 can potentially reduce lipid accumulation in tissues and improve metabolic health. Furthermore, ANGPTL3 has been shown to play a role in insulin sensitivity, making it a potential target for the treatment of type 2 diabetes.

Additionally, ANGPTL3 has been studied for its role in cardiovascular health. High levels of ANGPTL3 have been associated with an increased risk of coronary heart disease and stroke. Therefore, ANGPTL3 inhibitors could potentially be used for the prevention and treatment of these conditions.

Conclusion

In conclusion, Recombinant Human ANGPTL3 is a protein with a crucial role in lipid metabolism and cardiovascular health. Its structure, activity, and potential applications make it a promising therapeutic target for the treatment of dyslipidemia, obesity, type 2 diabetes, and cardiovascular diseases. Further research and clinical trials are needed to fully understand the potential of ANGPTL3 inhibitors in improving human health.